Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers
Launched by NATIONAL CANCER CENTER, KOREA · Nov 13, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a medication called Tripegfilgrastim to see if it can help reduce the risk of severe neutropenia, which is a dangerously low level of white blood cells, in patients with certain types of pancreatic and bile duct cancers that cannot be surgically removed. The trial is currently recruiting participants who are at least 19 years old, have been diagnosed with unresectable pancreaticobiliary cancer, and are scheduled to receive a specific chemotherapy treatment.
Participants in the trial will be randomly assigned to either receive the study drug or not, while their health will be closely monitored. The treatment may continue until a participant's disease worsens or they experience unacceptable side effects. Throughout the study, participants will have follow-up visits every two months to check on their health and survival until the trial concludes in June 2026. If you or someone you know is eligible and interested, this trial could provide an opportunity to receive additional support during chemotherapy.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients aged at least 19 years old, diagnosed with unresectable pancreaticobiliary cancer, and scheduled to receive chemotherapy using nal-IRI/5-FU/LV combination chemotherapy
- Exclusion Criteria:
- • Patients who refuse to sign the consent form Patients who have previously experienced severe neutropenia during chemotherapy
About National Cancer Center, Korea
The National Cancer Center Korea (NCC Korea) is a leading institution dedicated to cancer research, prevention, diagnosis, and treatment. As a prominent clinical trial sponsor, NCC Korea focuses on advancing innovative therapies and improving patient outcomes through rigorous scientific investigation and collaborative efforts. With a commitment to enhancing cancer care, the center conducts a wide range of clinical trials, fostering partnerships with academic institutions, healthcare providers, and industry stakeholders to translate research findings into effective clinical applications. Through its comprehensive approach, NCC Korea aims to contribute significantly to the global fight against cancer, ensuring that advancements in treatment are accessible to patients in need.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Goyang Si, Gyeonggi Do, Korea, Republic Of
Patients applied
Trial Officials
Sangmyung Woo, M.D
Principal Investigator
National Cancer Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported